Ciprobay 750 mg Film Coated Tablet: An Effective Antibiotic for Various Infections

Ciprobay 750 mg film-coated tablets are a medication containing ciprofloxacin, a potent antibiotic used to treat a wide range of bacterial infections. This blog post aims to provide an overview of Ciprobay tablets, including their composition, indications, dosage, precautions, and more.

Composition and Pharmaceutical Form

  • Each film-coated tablet of Ciprobay contains 750 mg of ciprofloxacin as hydrochloride.
  • The tablets are oblong, nearly white to slightly yellowish in color, and marked with “CIP 750” on one side and “BAYER” on the reverse side.
  • Ciprobay tablets are available in a film-coated form, ensuring optimal delivery and absorption of the medication.

Therapeutic Indications

Ciprobay 750 mg film-coated tablets are indicated for the treatment of the following infections:

  • Lower respiratory tract infections caused by Gram-negative bacteria, including exacerbations of chronic obstructive pulmonary disease, bronchopulmonary infections in cystic fibrosis patients, and pneumonia.
  • Chronic suppurative otitis media.
  • Acute exacerbation of chronic sinusitis, particularly if caused by Gram-negative bacteria.
  • Urinary tract infections.
  • Genital tract infections.
  • Gonococcal urethritis and cervicitis due to susceptible Neisseria gonorrhoeae.
  • Epididymo-orchitis, including cases caused by susceptible Neisseria gonorrhoeae.
  • Pelvic inflammatory disease, including cases caused by susceptible Neisseria gonorrhoeae.
  • Gastrointestinal tract infections, such as travelers’ diarrhea.
  • Intra-abdominal infections.
  • Skin and soft tissue infections caused by Gram-negative bacteria.
  • Malignant external otitis.
  • Infections of the bones and joints.
  • Prophylaxis of invasive infections due to Neisseria meningitidis.
  • Inhalation anthrax (post-exposure prophylaxis and curative treatment).
  • Management of patients with fever suspected to be due to a bacterial infection.
  • Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa.
  • Complicated urinary tract infections and pyelonephritis.
  • Anthrax (post-exposure prophylaxis and curative treatment).

It is important to note that treatment should be initiated by experienced physicians who are familiar with the treatment of cystic fibrosis and severe infections in children and adolescents.

Dosage and Administration

The dosage of Ciprobay tablets is determined based on the indication, severity and site of the infection, susceptibility of the causative organism(s), renal function of the patient, and body weight in children and adolescents. The duration of treatment depends on the severity of the illness and the clinical and bacteriological course.

Here are some recommended dosage guidelines:

  • Lower respiratory tract infections: 500 mg twice daily to 750 mg twice daily.
  • Upper urinary tract infections: 500 mg twice daily to 750 mg twice daily.
  • Genital tract infections: 500 mg twice daily.
  • Acute exacerbation of chronic sinusitis: 500 mg twice daily to 750 mg twice daily.
  • Uncomplicated cystitis: 500 mg as a single dose.
  • Gonococcal urethritis and cervicitis: 500 mg as a single dose.
  • Intra-abdominal infections: 500 mg twice daily to 750 mg twice daily.
  • Skin and soft tissue infections: 500 mg twice daily to 750 mg twice daily.
  • Bone and joint infections: 500 mg twice daily to 750 mg twice daily.
  • Inhalation anthrax: 500 mg twice daily to 750 mg twice daily.

Dosage adjustments may be necessary for elderly patients, patients with impaired renal function, and patients undergoing dialysis. It is important to follow the guidance of healthcare professionals regarding dosage and administration.

Precautions and Warnings

  • Ciprobay tablets are contraindicated in individuals with hypersensitivity to ciprofloxacin, other quinolones, or any of the excipients.
  • Concomitant administration of ciprofloxacin and tizanidine should be avoided.
  • Ciprofloxacin monotherapy is not suitable for the treatment of severe infections or infections caused by Gram-positive or anaerobic pathogens.
  • Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.
  • Care should be taken when treating gonococcal urethritis, cervicitis, epididymo-orchitis, and pelvic inflammatory diseases, as they may be caused by fluoroquinolone-resistant Neisseria gonorrhoeae isolates.
  • The prevalence of resistance to fluoroquinolones in Escherichia coli, the most common pathogen causing urinary tract infections, varies across regions, and this should be considered when prescribing ciprofloxacin.
  • Ciprobay tablets should be used in combination with other antimicrobial agents depending on the results of microbiological documentation.
  • Ciprofloxacin may cause tendinitis and tendon rupture, especially in the Achilles tendon. Patients should be cautious and report any signs of

tendon pain or swelling during ciprofloxacin treatment.

  • Ciprofloxacin should be used with caution in patients with myasthenia gravis, as it can exacerbate symptoms.
  • The use of ciprofloxacin in children and adolescents should follow official guidance and be initiated by experienced physicians.
  • Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals, and caution is advised when prescribing it to children and adolescents.
  • Patients with impaired renal or hepatic function may require dose adjustments based on their creatinine clearance or serum creatinine levels.
  • Ciprobay tablets should be taken orally with fluid, without chewing, and can be taken with or without food. However, they should not be taken with dairy products or mineral-fortified fruit juice.
  • In severe cases or when patients are unable to take tablets, intravenous ciprofloxacin may be initiated until oral administration is possible.
  • Hypersensitivity and allergic reactions, including anaphylaxis, may occur following a single dose of ciprofloxacin. If such a reaction occurs, the medication should be discontinued, and medical treatment should be sought.

It is important to follow the instructions and advice of healthcare professionals regarding the use of Ciprobay tablets, including dosage, duration of treatment, and any specific precautions or warnings.

Conclusion

Ciprobay 750 mg film-coated tablets are a versatile antibiotic used for the treatment of various bacterial infections. With ciprofloxacin as the active ingredient, these tablets provide an effective therapeutic option for conditions such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. However, it is crucial to use them responsibly, following the guidance of healthcare professionals and considering factors such as susceptibility to ciprofloxacin, resistance patterns, and individual patient characteristics. Ciprobay tablets offer a valuable treatment option, contributing to the management and resolution of bacterial infections.


Discover more from Pharma Guide

Subscribe to get the latest posts to your email.